Jumbo Drug Bank Co., Ltd.

Guizhou Inochini Technology Co., Ltd

Westvac Biopharma Co., Ltd.

XiaWei Wei

Jian Li

Shuhui Chen

Lingyun Wu

Lele Zhao

Wei Zheng

Ning Jiang

Peng Zhang

Guoping Hu

Chengde Wu

Yuquan Wei

Chen Zhang

Chunli Shen

Zhaoguo Chen

Cailin Wang

Peng Yang

Zhiwei Zhao

Xia Zhao

Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyrrolotriazine compounds acting as MNK inhibitor

Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.

Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors

The present invention belongs to the field of biological medicine, particularly to a novel tumor vaccine. In order to solve the problem in the art that no technical scheme is available for generating lasting and high-effective anti-tumor immune responses, the present invention provides a tumor vaccine mainly containing a complex as a main active ingredient, wherein the complex is formed by nucleic acid, especially replicable nucleic acid not expressing exogenous gene, and cationic biomaterial. The nucleic acid and the cationic biomaterial in the tumor vaccine according to the present invention have synergistic interactions on direct killing of tumor cells, and induction of the innate immune response and adaptive immune response of body against tumor. In addition, the prepared tumor vaccine has simple drug component and is easy to produce and maintain quality control. The tumor vaccine has a good prospect for application.

Tumor vaccine and uses thereof

Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Dimethylphosphine oxide compound

Growing community of inventors

Sichuan, China

XiaWei Wei